Review Article

Hiv and Lymphoma: from Epidemiology to Clinical Management

Alessandro Re, Chiara Cattaneo and Giuseppe Rossi.

Ematologia, Spedali Civili di Brescia.

Competing interests: The authors have declared that no competing interests exist.

Abstract. Patients infected with human immunodeficiency virus (HIV) are at increased risk for developing both non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). Even if this risk has decreased for NHL after the introduction of combination antiretroviral therapy (cART), they remain the most common acquired immune deficiency syndrome (AIDS)-related cancer in the developed world. They are almost always of B-cell origin, and some specific lymphoma types are more common than others. Some of these lymphoma types can occur in both HIV-uninfected and infected patients, while others preferentially develop in the context of AIDS. HIV-associated lymphoma differs from lymphoma in the HIV negative population in that they more often present with advanced disease, systemic symptoms, and extranodal involvement and are frequently associated with oncogenic viruses (Epstein-Barr virus and/or human herpesvirus-8). Before the introduction of cART, most of these patients could not tolerate the treatment strategies routinely employed in the HIV-negative population. The widespread use of cART has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that nowadays can be compared to those seen in non-HIV infected patients. However, a great deal of attention should be paid to opportunistic infections and other infectious complications, cART-chemotherapy interactions, and potential cumulative toxicity. In the context of relatively sparse prospective and randomized trials, the optimal treatment of AIDS-related lymphomas remains a challenge, particularly in patients with severe immunosuppression. This paper will address epidemiology, pathogenesis, and therapeutic strategies in HIV-associated NHL and HL.

Keywords: HIV; Lymphoma; ARL.

Citation: Re A., Cattaneo C., Rossi G. Hiv and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis 2019, 11(1): e2019004, DOI: http://dx.doi.org/10.4084/MJHID.2019.004

Published: January 1, 2019 Received: September 12, 2018 Accepted: November 23, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Alessandro Re, Ematologia, Spedali Civili di Brescia, Piazzale Spedali Civili n 1, 25123 Brescia, Italy. Tel: +390303995438, Fax: +300303996135. E-mail: alessandro.re@asst-spedalicivili.it

Introduction. Since the beginning of the acquired immune deficiency syndrome (AIDS) epidemic, in the early eighties, the association between lymphomas and the acquired immunodeficiency became evident and was reported before the discovery of human immunodeficiency virus (HIV) as the responsible agent for the syndrome. Diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) and primary central nervous system lymphoma (PCNSL) were soon recognized as AIDS-defining event in patients who lived with HIV infection (PLWH). Most of these patients could not tolerate the dosage of chemotherapy (CT) routinely employed in the HIV-negative population, and the majority died of these diseases. After the advent of combination antiretroviral therapy (cART) in 1996, the death rate from AIDS dramatically decreased as the risk of new opportunistic infections and the incidence of Kaposi’s Sarcoma (KS). The incidence of lymphomas, however, did not decrease as sharply, and they became the most common AIDS-related cancer in the developed world.2 The widespread use of cART has given PLWH the opportunity to receive and tolerate a standard dose
of CT and has increased the probability of cure. However, in the context of relatively sparse prospective and randomized trials, the optimal treatment of AIDS-related lymphomas (ARL) remains a challenge, particularly in patients with severe immunosuppression. In this review, we report the main information concerning epidemiology and pathogenesis of ARL and summarize the therapeutic strategies in Hodgkin (HL) and non-Hodgkin lymphoma (NHL), analyzing the lymphoma subtypes individually. We also briefly discuss some specific aspects of ARL clinical management, such as the use of concomitant cART, infectious prophylaxis, and prophylaxis of central nervous system (CNS) involvement by NHL. We also describe the main results with autologous (ASCT) and allogeneic stem cell transplantation (AlloSCT).

**Epidemiology.** ARL usually present with advanced-stage disease and follow an aggressive clinical course. They are almost always of B-cell origin, and some specific lymphoma types are more common than others. Some of these lymphoma types can occur in both HIV-uninfected and infected patients, while others preferentially develop in the context of AIDS or in patients with other immunodeficiencies (Table 1). In an early phase of the HIV epidemic, the relative risk to develop NHL for AIDS patients was >100-fold higher compared to the general population. After entering the cART era, the incidence of ARL has substantially decreased; however, they remain clearly higher than in the general population. In Italy, 500 fold higher risk to develop NHL than in the general population was reported in persons with AIDS between 1986-1996 and 90 fold higher between 1997-2004. Actually, a wide range of increased risks for lymphoma has been reported in population-based studies, mainly depending on the population under observation and the calendar years examined. In the latest studies conducted in Switzerland and in the USA the relative increase in patients with HIV/AIDS appears lower, ranging between 10-20 fold higher than in the general population. A consortium of North American cohorts estimated that the probability to develop NHL (i.e., cumulative incidence) among PLWH in the cART era is 4%, even if it appears declining across 96-2009. However, the advent of cART had a different impact on the epidemiology of the various subtypes of NHL. While PCNSL dramatically decreased, the decline in DLBCL incidence was less impressive, and BL was not substantially affected. The incidence of classical HL in PLWH is approximately 5 fold to 20 fold higher than in the general HIV negative population, and the risk of HL has remained stable or even increased since the introduction of cART. Even in the cART era, it appears that people with AIDS and NHL or HL have a significantly reduced survival in comparison with an HIV-negative population with the same diseases. Report from the Italian Cancer Registry showed, for the period 1996-2005, 5-year survival of 64% among HIV-uninfected patients with NHL, compared to 25% among AIDS patients with NHL, and respectively 86% vs. 42% among patients with HL.

**Pathogenesis.** While it is clear that HIV increases the lymphoma risk, there is no evidence that HIV infection by itself leads to cell transformation. Only recently a possible direct effect of HIV through secreted or transmitted viral proteins has been hypothesised: some experimental evidence support oncogenic functions of HIV Tat, and specific variants of HIV p17 has been found to be associated with the development of lymphoma. However, HIV does not infect the lymphoma cells and is thought to have mainly an indirect role in lymphomagenesis, primarily causing immunosuppression, with the consequent attenuation of tumor surveillance. Indeed, an inverse association between CD4+ cell count and NHL onset has been demonstrated by several studies. However, as the risk of lymphoma in PLWH remains high even after the widespread use of cART, the relationship between immune status and lymphoma development appears more complex. HIV-associated DLBCL and PCNSL

| Lymphomas also occurring in immunocompetent patients |
|------------------------------------------------------|
| Burkitt lymphoma                                      |
| Diffuse large B-cell lymphoma                         |
| Hodgkin lymphoma                                      |
| Other lymphomas (MALT lymphoma; peripheral T-cell and NK-cell lymphoma) |
| Lymphoma occurring more specifically in HIV+ patients |
| primary effusion lymphoma (PEL)                      |
| plasmablastic lymphoma                                |
| Lymphoma arising in HHV8-associated multicentric Castelmann Disease |
| Lymphomas occurring in other immunodeficiency states |
| Polymorphic lymphoid proliferations resembling PTLD   |

* Raphael M, Said J, Borish B, Ceserman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.

---

Table 1. Lymphomas associated with HIV infection (according to WHO classification of tumours of haematopoietic and lymphoid tissues, 2008) *(Ref.4).*

---

**www.mjhid.org** Mediterr J Hematol Infect Dis 2019; 11; e2019004

---

Pag. 2 / 17
are often associated with Epstein-Barr virus (EBV) infection and tend to occur when immunosuppression is more pronounced.

In contrast, HIV-associated BL tends to occur earlier in the course of the illness when CD4 counts are somewhat better preserved.\(^1\) HL occurs with relatively high frequency during the first few months after initiation of cART as the CD4 cell counts are increasing, suggesting that HL may be driven by immune recovery rather than by cell count depletion, at least in some cases.\(^2\) Anyway, while elimination of HIV from peripheral blood can be achieved with cART, viral replication can still occur in lymphoid tissues.\(^3\) Moreover, the specific and direct role of other oncogenic viruses, such as EBV and human herpesvirus-8 (HHV-8), in ARL pathogenesis is well documented, and most lymphomas with excess risk among PLWH are associated with these virus infections (Table 2). The incidence of some EBV-associated lymphomas, including BL and HL, remains high in the cART era and rates of HHV8-associated primary effusion lymphoma (PEL) and multicenter Castleman’s disease (MCD) are unaffected by the use of cART.\(^4\) It is also known that chronic inflammation could contribute to lymphomagenesis; in clinical observation, even with long-term virological suppression, inflammatory biomarkers remain at high levels in HIV-infected people.\(^5\) In conclusion, HIV creates an environment in which chronic antigen stimulation, cytokine dysregulation, and coinfection with oncogenic viruses, in the background of genetic abnormalities and disrupted immune surveillance to tumor antigens, can lead to the emergence of monoclonal B cells.\(^6,7\)

**Clinical Management.** After a diagnosis of an ARL, in addition to the usual evaluation of lymphoid malignancy, assessment of HIV disease status including CD4 cell counts, HIV viral load, sensitivity of the virus to available antiretroviral drugs and prior history of AIDS-related complications is necessary. Understanding the prospects for successful long-term HIV management is essential. A patient with a high viral load and poor immune function, who is cART naive, is likely to respond well to cART and have fewer complications of CT compared with a patient who has resistant HIV as a result of having had multiple cART regimens.

**Combination of HIV treatment and chemotherapy.** Several HIV medications and CT agents have overlapping side effects, such as renal and hepatic toxicity, myelosuppression and peripheral neuropathy.\(^8\) In addition, many CT drugs and HIV medications are metabolized through the cytochrome p450 (CYP) enzyme system of the liver. The cART can augment or inhibit the clearance of CT agents and which can lead to either increased CT-associated toxicity or a decrease in treatment efficacy.\(^9,10\) Notably, the HIV protease inhibitor ritonavir is a particularly potent inhibitor of the CYP system that can diminish the clearance of vinca alkaloids and should be avoided during ABVD therapy for HL.\(^11\) Several authors propose antiretroviral discontinuation during lymphoma treatment.\(^12\) However, a retrospective analysis of the trial AMC034 showed that in patients treated with concurrent cART dose adjusted-EPOCH + rituximab (R-DA-EPOCH) is well-tolerated and allows for faster recovery of immune function compared to consecutive CT and cART.\(^13\) A meta-analysis of 1546 patients with HIV-associated NHL demonstrated that concurrent cART and CT was associated with statistically improved complete remission (CR) rates with a trend toward improved overall survival (OS).\(^14\) Currently, it is suggested that all HIV-infected patients with malignancies should continue cART during CT.\(^15,16\) There is some evidence of the detrimental effect of protease inhibitor (PI)-based cART, due to excess of toxicity and the use of integrase inhibitors might bring advantages concerning drug-drug interactions and allows for a faster decline of the viremia.\(^17\)

**Infection prophylaxis.** No comparative studies exist, and only one guideline has been published for opportunistic infections (OI) prophylaxis in HIV-associated malignancies.\(^18\) Cotrimoxazole prophylaxis against *P. jiroveci* pneumonia and toxoplasmosis should be administered during immuno-suppressive treatment regardless of the CD4 cell count.\(^19\) Other infections’ prophylaxis is generally recommended at least in

---

**Table 2. HIV-associated lymphomas and oncogenic viruses.**

| HIV-associated lymphomas | Associated oncogenic virus |
|--------------------------|---------------------------|
| DLBCL                    | Immunoblastic EBV 90%     |
|                          | Centroblastic EBV 30% (Ref. 4) |
| Burkitt lymphoma         | EBV 25-40% (Ref. 21)      |
| PEL                      | EBV 80-100%               |
|                          | HHV8 100% (Ref. 4,83)    |
| PCNSL                    | EBV 80-100% (Ref. 94)    |
| PBL                      | EBV 90-100% (Ref. 72)    |
| Hodgkin lymphoma         | EBV 90-100% (Ref. 4)     |
| MCD                      | HHV8 100% (Ref. 105)     |

DLBCL (diffuse large B-cell lymphoma), PEL (primary effusion lymphoma), PCNSL (primary central nervous system lymphoma), PBL (plasmablastic lymphoma), MCD (multicenter Castleman’s disease), EBV (Epstein-Barr virus), HHV8 (human herpesvirus 8)
Diffuse large B cell lymphoma. DLBCL, the most frequent ARL, often presents at an advanced stage and with B symptoms and extranodal tissue is frequently involved, mainly in severely immunosuppressed patients. Prognosis is determined by patient-, lymphoma- and HIV-specific factors. The International Prognostic Index (IPI) has been extensively validated and remain a reliable predictor of outcomes. Low CD4 counts have been reported as predictors of poor survival in several studies, while others have not found such an association, especially in the cART era. An AIDS-related lymphoma IPI has been recently developed, that employs the Age Adjusted-IPI and an HIV severity score incorporating CD4 count, viral load, and prior history of AIDS to risk-stratify ARL. No consensus has emerged in the HIV setting for distribution and relation to outcome of biologically distinct subtypes of DLBCL, germinal center B-cell and activated B-cell and the proportion and outcome of “double hit” (characterized by rearrangement of c-myc and either bcl-2 or bcl-6) and “double-expressor” DLBC lymphoma (overexpression of c-myc and bcl-2) has not been extensively studied. Treatment recommendations for DLBCL in HIV infected patients are mostly based on evidence from phase 2 trials, retrospective series or expert opinion. Interpretation of the literature is complicated by the fact that in many early studies patients with different subtypes of aggressive NHL were all treated with the same regimens and frequently composite outcomes were reported. A significant positive impact on outcomes for HIV-related DLBCL has been reported after the introduction of cART. North American and European cooperative group trials reported CR rates of 48-63% and 1-year overall survival (OS) of 60-80% with CHOP in the cART era. Moreover, infusional regimens were explored; CDE results were in line with what seen with CHOP, while 39 patients (79% with DLBCL and 18% BL) treated at National Cancer Institute (NCI) with DA-EPOCH, obtained a CR rate of 74%, and a median OS of 60%, comparable with HIV negative population treated with the same regimen at NCI at the same time. After successful addition of the CD20-directed monoclonal antibody, rituximab to CHOP therapy in HIV negative patients, a direct comparison of CHOP vs. rituximab-CHOP (R-CHOP) in HIV-associated NHL have been conducted in the AMC010 trial. One hundred and fifty HIV-positive patients with intermediate and high-grade CD20-pos NHL (80% of patients had DLBCL) were randomized in a 1:2 fashion to receive either CHOP or R-CHOP followed by three-monthly rituximab maintenance. Despite higher CR/CR unconfirmed rate (58% vs. 47%), and less lymphoma-related deaths in the R-CHOP arm (14% vs. 29%), there were no statistical differences in progression-free survival (PFS) (median t10 months vs. 9) and OS (32 months vs. 25). A possible explanation for the lack of benefit from rituximab might be the high treatment-related mortality (14% in the rituximab arm vs. 2%; P=0.03), which was particularly high (36%) for pts with CD4 count < 50/mcL in R-CHOP arm. Moreover, 40% of the infectious deaths was during rituximab maintenance, and in this study routine neutropenic antibiotic prophylaxis was not employed. Several phase 2 trials along with a pooled analysis from 19 trials demonstrated that the addition of rituximab to the CHOP regimen was beneficial (CR rate ranged between 58-77%) and did not lead to a higher rate of death from infectious complications. Similarly, the addition of rituximab to CDE resulted in higher remission rate (RR) and improved survival. Then, all trials in CD20 positive ARL nowadays include rituximab. Some trials exclude patients with CD4 < 50/mcL; however, rituximab has been used safely in patients with < 50/mcL CD4 count in many studies. Several prospective trials combined rituximab with EPOCH. In AMC034, a randomized phase 2 trial, rituximab was given either consecutively with EPOCH or sequentially. One hundred and 6 patients were enrolled (75% with DLBCL and 25% with BL-like); CR was 73% in the concurrent arm (71% for DLBCL) vs. 55% in the sequential arm (46% for DLBCL). 2 years OS and PFS were 70% vs. 67% and 66% vs. 63% in the concurrent vs. sequential arm. The NCI explored short-course-EPOCH with dose-dense rituximab (SC-EPOCH-RR) in 33 patients, with rituximab given on day 1 and 5 of each cycle. Patients received one cycle after 18fluorodeoxyglucose positron emission tomography (PET) negativity, with PET evaluated each cycle after the second. CR was 91% after a median of 3 cycles, with PFS and OS at five years 84% and 68% respectively. Indirect evidence from retrospective analyses suggests that in ARL EPOCH might be more efficacious than CHOP. In DLBCL an improved OS was found in a retrospective analysis of pooled data with DA-EPOCH vs. CHOP; however, the difference between CHOP plus rituximab vs. EPOCH plus rituximab was not significant. Moreover, no randomized trial comparing R-CHOP vs R-EPOCH has been performed in HIV positive patients and in HIV negative population a randomized prospective trial showed DA-R-EPOCH and R-CHOP to be equally effective. Table 3 shows the results of V the main studies investigating the first-line treatment of HIV-related DLBCL in the cART era. At present both regimens are considered a valid choice of CT for patients with HIV-associated DLBCL and outcomes approach those for HIV negative patients in the current era. Therapeutic options for relapsed/refractory (R/R) disease have been poorly investigated.
| Therapy and study type                                      | Number of patients | Histology                      | Complete Remission | Survival                                      | Reference   |
|------------------------------------------------------------|--------------------|--------------------------------|---------------------|-----------------------------------------------|-------------|
| Modified (m) CHOP and CHOP (phase II)                      | 65 (mCHOP 40; CHOP 25) | Intermediate- and high-grade NHL | mCHOP: 30%          | mCHOP: median DFS 16 ms CHOP: median DFS NR | Ratner (45) |
| DA-EPOCH (phase II)*                                       | 39                 | Aggressive B NHL               | 74%                 | PFS at 53 ms 73% OS at 53 ms 60%              | Little (31) |
| CDE (phase II)*                                            | 98                 | Intermediate- and high-grade NHL | 45%                 | 2y-FFS 36% 2Y-OS 43%                          | Sparano (47) |
| R-CDE (pooled results of 3 phase II)                       | 74                 | CD20+ NHL                      | 70%                 | 2y-PFS 59% 2y-OS 64%                          | Spina (52)  |
| CHOP vs R-CHOP (phase III)                                 | 150 (CHOP 51; R-CHOP 99) | B-cell NHL                     | CHOP: 47% R-CHOP: 58% | CHOP: median PFS: 38 wks OS: 110 wks R-CHOP: median PFS 45 wks, OS:139 wks | Kaplan (48) |
| CHOP (phase II)                                            | 72                 | Intermediate- and high-grade NHL | 63%                 | Median OS 26.1 months                         | Weiss (46) |
| R-CHOP (phase II)                                          | 52                 | High-grade B-cell-NHL          | 77%                 | 2y-PFS 69% 2y-OS 75%                          | Boué (49)  |
| R-CHOP (phase II)                                          | 80                 | DLBCL                          | 69%                 | 3y-DFS 77% 3y-OS 56%                          | Ribera (50) |
| R-EPOCH (n=51) or EPOCH > R (n=55) (phase II randomized)   | 106 (R-EPOCH 51; EPOCH > R 55) | DLBCL, BL, BLL, aggressive CD20+ NHL | R-EPOCH: 69% EPOCH>R: 53% | R-EPOCH: 2y-PFS 66% 2y-OS 70% EPOCH>R: 2y-PFS 63% 2y-OS 67% | Sparano (54) |
| SC-EPOCH-RR (phase II)                                     | 33                 | DLBCL                          | 91%                 | 5y-PFS 84% 5y-OS 68%                          | Dunleavy (43) |
| DR-COP (phase II)                                          | 40                 | CD20 + aggressive NHL          | 48%                 | 2y-PFS 52% 2y-OS 62%                          | Levine (52) |

cART: combination antiretroviral therapy, NHL: non-Hodgkin lymphoma, DLBCL: diffuse large B-cell lymphoma, BL: Burkitt lymphoma, BLL: Burkitt-like lymphoma, CHOP: Cyclophosphamide, vincristine, doxorubicin, and prednisone, CDE: cyclophosphamide, doxorubicin, and etoposide, DA-EPOCH: dose adjusted etoposide, prednisone, doxorubicin, cyclophosphamide, and vincristine, COMP: liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone, R-CHOP: rituximab + CHOP, R-CDE: rituximab + CDE, R-EPOCH: rituximab concurrent with EPOCH, EPOCH > R: rituximab sequential after EPOCH, SC-EPOCH-RR: short-course EPOCH with dose-dense rituximab, DR-COP: pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone, DFS: disease free survival, FFS: failure free survival, PFS: progression free survival, OS: overall survival, NR: not reached, wks: weeks, ms: months.

* Not all patients were enrolled in the cART era
The standard of care in HIV-negative population is salvage therapy followed by high-dose CT and ASCT. The one year OS of patients with R/R ARL who did not undergo ASCT was only 37%, in a retrospective series of patients treated by several American institutions; patients who underwent ASCT as part of their salvage therapy lived longer (1 year OS 63.2%). Since in the cART era several clinical trials have demonstrated that HIV-infected patients can safely and successfully undergo ASCT, there is consensus to approach HIV positive patients with R/R DLBCL like immunocompetent patients. High dose salvage regimens such as ICE, DHAP, ESHAP, GDP, with rituximab appear to have similar efficacy, and patients with chemosensitive disease who are transplant eligible should proceed to ASCT (see dedicated paragraph on ASCT in the HIV setting). At present, we treat HIV positive patients with DLBCL in the first line with R-CHOP and consider consolidation with HDT in patients with high risk disease according to IPI, in cART responding patients with permissive immune status. In R/R disease we use conventional salvage CT (we prefer ESHAP) followed by ASCT in responding patients.

**Burkitt lymphoma.** BL, the second commonest subtype of ARL, occurs in individuals with relatively preserved CD4 counts. Patients typically present with poor Performance Status (PS) and high lactate dehydrogenase level. Extra-nodal involvement is common, and the incidence of CNS involvement ranges from 8 to 28%. In the pre-cART era, HIV patients with BL were usually treated with the same non-intensive chemotherapy regimens as for DLBCL, with similar unsatisfactory results. After the advent of cART, survival in BL remained poor, with CHOP or M-BACOD-based therapies. Spina et al. demonstrated that BL had a worse prognosis with R-CDE compared to DLBCL. This led to the investigation of the intensive regimens commonly used in immunocompetent patients with BL (HyperCVAD, CODOX-M/IVAC, LMB-86), and several retrospective, and phase II studies showed their feasibility and efficacy in the HIV setting (CR rates 63-92% and OS 47-73%), even if they appeared more toxic than in the general population. Moreover, several studies demonstrated the feasibility of adding rituximab to intensive regimens. Ribera et al. reported the results of B-ALL/NHL2002 study, that showed comparable outcomes in patients with and without HIV (CR 82% vs 87% and 4 years OS 63% vs 78%) in spite of a higher incidence of severe mucositis and infections in HIV positive patients, with 13% of patients who died in induction. To reduce the toxicity of dose-intensive regimens, the AIDS Malignancy Consortium (AMC) conducted a study (AMC048) with a modified CODOX-M/IVAC-R regimen in 34 HIV-positive patients. A 2 years OS of 69% was reported with no severe mucositis and only one treatment-related death. Dunleavy et al. treated 11 patients with SC-EPOCH-RR with an excellent OS 90% at 73 months of follow-up (69). Recently Ferreri AJM et al. reported the safety and activity of the Carmen Trial, a phase II trial including a dose-dense and short-term chemotherapy program, with ASCT as first-line consolidation for patients who did not achieve CR after induction. Table 4 shows the results of the main studies investigating the treatment of HIV-related BL in the cART era. We suggest treating HIV positive patients with the regimens specifically designed for HIV-positive subjects with BL. As an alternative, the same intensive regimens commonly used for immunocompetent patients in a specific center, including rituximab, can be used; however, dose-adjustment might be required, at least in patients with advanced HIV disease.

**Plasmablastic lymphoma.** PBL was initially described in the late nineties as a rare variant of DLBCL, with plasmacytoid appearance, affecting primarily mucosal sites, particularly the oropharynx, and occurring predominantly in HIV positive patients. Median CD4 count at presentation ranges from 87-206 cells/ml. It is characterized by loss of the mature B cell markers including CD20, and an elevated proliferation index. It is almost always associated with EBV, and up to 50% of the cases carry a translocation involving c-MYC, which might have a negative prognostic impact. No prospective trials have been conducted in patients with PBL, and the majority of the studies report poor OS (5-17 months) with a variety of regimens, including CHOP, CHOP-like regimens, EPOCH, CDE, CODOX-M/IVAC. Castillo et al. reported no OS benefit of intensive regimens like CODOX-M/IVAC vs. CHOP or CHOP-like regimens. Ibrahim et al. reported a single institution experience on 25 patients showing improved OS with DA-EPOCH vs. CHOP (17 vs. 7 months). More encouraging results have been recently reported in a small series by Ariela Noy et al. (CR 70% achieved with either CHOP- or EPOCH-based regimens and one year OS 67%). Reasons for different outcomes reported by different authors are not clear. Cattaneo et al. reported their single institution experience, showing 67% three years OS in 13 patients with PBL treated during the cART era. In this series treatment strategy included CHOP-14 regimen and extensive use of radiotherapy (RT); moreover, five patients received ASCT as consolidation, an approach that seems promising in this setting. We suggest treating PBL patients with intensive chemotherapy (CHOP-14 as an option) followed by RT, at least in a localized stage. Early consolidation with ASCT might be an option for advanced stage patients and the cART should be concurrently used.

However, new therapies seem advisable to improve outcomes and should be investigated in first and/or salvage setting. Bortezomib is of particular interests as
it is also particularly effective against multiple myeloma, which shares many molecular and immunohistochemical features with PBL; several reports have documented activity of bortezomib in PBL. Moreover, lenalidomide as a single agent has been used with some success in relapsed/refractory PBL and in combination with CT in the first-line setting. 

**Primary effusion lymphoma.** PEL is a rare B-cell lymphoma characterized by effusions involving the pleura, pericardium, and/or peritoneum; however, a rare solid extra-cavitary variant has been described. Severe immunosuppression with low CD4+ cell counts is common. Most PELs have lymphocyte activation markers (CD30 and CD38) without normal B-cell markers (CD19 and CD20). HHV8 has a pathogenetic role and is present in almost 100% of cases. Other HHV8-related complications such as KS or MCD may precede or occur concurrently with PEL. The most used CT regimen is CHOP that allows achieving CR rate of 40-50%, with median survival around six months. However, some patients do achieve long-term remissions, but predictive factors have not been identified. Reports of outcomes using more intensive CT are controversial and seem to indicate that intensifying CT is of limited benefit. Anecdotal reports of cases responding to cART alone have been reported. The effect of anti-HHV-8 therapy remains unproven. Bortezomib has been used in combination with conventional CT with promising results. A case report describes sustained remission in an HIV negative patients treated with single-agent lenalidomide. Recently, Shah NN et al. has reported the successful use of daratumumab, a CD38-directed human IgG1k monoclonal antibody, to treat a case of HIV-related PEL. Anti-CD30 directed treatment also showed promise.

In conclusion, the optimal first-line treatment for HIV-related PEL is undefined. Standard CHOP therapy or more intensive CT regimens in young patients with advanced disease are acceptable approaches. Even if newer therapies are advocated, no specific strategy can be recommended at present.

**Primary central nervous system lymphoma.** PCNSL is a subtype of DLBCL with a post-germinal center
phenotype. The immunophenotype of PCNSL in HIV positive subjects differs from immunocompetent patients; EBV is almost always detectable in lymphoma cells and cerebrospinal fluid, while it is rarely present in PCNSL in the HIV negative population. Clinical findings and standard radiological investigations cannot provide a definitive diagnosis, that usually requires brain biopsy; however, the combination of detectable EBV in cerebrospinal fluid (CSF) and consistent radiological findings in a severely immunosuppressed HIV positive patients may be sufficient in selected cases. HIV positive patients with PCNSL usually have advanced immunosuppression and CD4 count < 50/mmc, making impossible the administration of high dose (HD) methotrexate (MTX) and cytosine arabinoside, as employed in immunocompetent patients (95), in a high proportion of patients. Whole brain RT was used extensively as the only therapy in the pre-cART era, but with dismal outcomes and survival of a few months. The advent of cART led to a modest improvement in survival. Ancedotal literature suggests that the prompt implementation of cART in patients with HIV-PCNSL could result in long-term remission; however, this procedure should be reserved for carefully selected patients, not eligible for intensive CT. At least two retrospective study showed the feasibility and efficacy of combined cART plus HD-MTX, at least in selected patients. Moullignier et al. analyzed 51 patients consecutively treated in France with HD-MTX (3 gr/ms) and cART and reported a median OS of 5.7 years. No one died of acute treatment-related toxicity. Gupta et al. reported on 20 patients treated with cART plus MTX-based regimens from several centers in the US; median OS was not yet reached after a median follow-up of 27 months. In this experience CD4 reconstitution with cART administered during HD-MTX correlates with long-term survival; rituximab did not add untoward toxicity while the addition of other agents to HD-MTX did not improve outcome and was associated with an increased rate of neutropenic complications and a more attenuated rate of CD4 recovery. Thus, in the absence of prospective studies, we suggest treating cART responding patients with HD MTX and rituximab. If induction treatment is well tolerated and a response is documented, consolidation with HDT and ASCT could be considered in selected patients. Indeed, ASCT seems to have a beneficial role in HIV positive PCNSL patients, and which deserves further evaluation.

**Multicentric Castleman’s Disease.** Even if a polyclonal disease, MCD is an aggressive B-cell lymphoproliferative disorder with an increased incidence in PLWH, that can be life-threatening, either through multiple organ failure or the development of NHL. It presents with various clinical features and lymph nodes and spleen enlargements, with usually B symptoms, weakness, and malaise. A hemophagocytic syndrome may complicate the clinical course in a non-negligible number of cases. Almost all MCD cases in HIV positive subjects are associated with lytically active HHV-8 infection. HHV-8 encodes a viral IL-6 that plays a major role in the pathophysiology of the disease and the level of plasma HHV8 DNA is a helpful biomarker to monitor disease activity and response to therapy. A variety of treatment strategies have been reported, and there is no widely accepted standard of care. Usually, the treatment approach is designed according to the severity of the disease. The prognosis has improved in recent years, mainly after the introduction of cART (even if MCD can occur or worsen soon after initiation of cART) and treatment with rituximab. Rituximab showed its efficacy in 2 prospective trials, and there is evidence that rituximab decreases the risk of subsequent development of NH. Notably, an association with KS has been reported up to 70% of cases, and KS may reactivate during treatment with rituximab. Cytotoxic CT as a single agent (etoposide seems to give the best results) or in combination are effective and are considered the therapy of choice in patients with severe disease. The utility of antivirals agents in MCD has not been demonstrated. We usually treat patients with a combination of cART, rituximab, and antiviral therapy such as valganciclovir, reserving combination CT (such as CHOP) + rituximab in severe or not responding disease. Targeting IL-6 and IL6 receptor with monoclonal antibodies appears as an attractive approach and could be considered at least in selected patients.

**Hodgkin lymphoma.** HL in PLWH frequently presents with unfavorable features such as advanced-stage, extranodal disease, and bone marrow involvement, and is associated with EBV in 80-100% of cases. The mixed cellularity subtype is the most commonly observed. Median CD4 counts at HL diagnosis ranges between 150 and 260 cells/mcL, and its incidence has remained stable or may have even increased after the advent of cART. Before the introduction of cART, the prognosis was poorer compared to the general population, mainly for poor tolerance of CT, with high rates of OI and toxic deaths. CR and OS rates improved significantly in patients responding to cART; indeed, the low CD4 count remains an independent adverse prognostic factor. While a prospective study with Stanford V and concomitant cART resulted in 3-year OS 51%, higher cure rates have been reported with ABVD and cART. Three large retrospective studies reported CR rate of 74-87% and five years OS of 76-81%. Notably, in two of these studies, a comparison was made with HIV negative patients, and the HIV status, which did not result to affect the outcome. A relatively large prospective study on a stage- and risk-adapted treatment strategy, including ABVD, baseline BEACOPP, and
involved field RT has been reported by Hentrich et al. CR rates were respectively 96%, 100%, and 86% for early favorable-, early unfavorable-, and advanced-stage disease and 2 years OS 95.7%, 100%, and 86.8%. However, BEACOPP was toxic, dose delays and dose reductions were common, and treatment-related mortality was 7% in patients with advanced disease.\textsuperscript{121} Then, nowadays prognosis for patients with HL and HIV infection approaches that of patients without HIV infection, and a stage adapted treatment appears feasible. ABVD with or without RT (with the same indication for RT as in HIV negative population) is now seen as the standard of care for front-line therapy. However, a higher incidence of toxicity might be expected compared to the general population. The role of BEACOPP is not clear as the experience are very limited and contrasting results have been reported.\textsuperscript{122}

Table 5 shows the results of the main studies investigating the first-line treatments of HIV-related HL in the cART era.

Patients who relapse or have primary refractory disease should be considered for conventional salvage CT followed by ASCT as several experiences have reported the feasibility and efficacy of this approach in the HIV setting (see dedicated paragraph). Only limited evidence on the role of PET scans in the diagnosis of HL, and interim evaluation is available in HIV positive patients. As a general rule, PET scan results should be interpreted with caution as PET can be falsely positive in particular in cART- naïve or viremic patients. A recent Intergroup Cooperative trial that used FDG-PET after cycle 2 of ABVD to guide further therapy included 12 pts with HIV infection; even if based on a very small experience, the investigators concluded that it might be appropriate to include HIV patients in further studies of response-adapted therapy.\textsuperscript{123} Novel agents, such as the CD30-directed immunoconjugate brentuximab vedotin (BV), are under evaluation in the HIV setting.\textsuperscript{124} The combination of BV with doxorubicin, vinblastine, and dacarbazine showed safety in newly diagnosed HIV-associated HL in a phase I study (no dose-limiting toxicity was found and six patients who completed therapy achieved CR);\textsuperscript{125} the phase II portion of this trial is ongoing (NCT01771107). Immunomodulatory approaches, such as checkpoint inhibition with anti-PD-1 agents, may also be investigated in future studies, with some cautions due to the peculiarity of the HIV setting.\textsuperscript{126}

We treat HIV positive patients in the first line with ABVD +/- RT in a stage- and risk-adapted strategy.

Table 5. Main reported series of front line therapy for HIV-associated Hodgkin lymphoma in the cART era.

| Therapy and study type | Number of patients | Stage III/IV (or risk-group) | Complete remission | Survival | Reference |
|------------------------|--------------------|------------------------------|-------------------|----------|-----------|
| Stanford V (phase II)  | 59                 | 71%                          | 81%               | 3y-OS 51% | Spina (117) |
| BEACOPP ** (phase II) | 12                 | 82%                          | 83%               | 3y-OS 75% | Hartmann (122) |
| ABVD (retrospective)  | 62                 | 100%                         | 87%               | 5y-EFS 71% | Xicoy (118) |
| VEBEP (phase II)      | 73                 | 70%                          | 67%               | 3y-OS 66% | Spina (116) |
| ABVD (retrospective)  | 93                 | 80%                          | 74%               | 5y-EFS 59% | Montoto (119) |
| ABVD/BEACOPP (phase II) | 23              | Early favourable | 96%               | 2y-OS 96% | Hentrich (121) |
|                        | 14                 | Early unfavourable | 100%              | 2y-OS 100% |           |
|                        | 71                 | Advanced                  | 86%               | 2y-OS 87% |           |
| ABVD* (retrospective) | 68                 | 76%                          | Not reported       | 2y-PFS 89% | Besson (120) |
| ABD-BV (phase I)      | 6                  | 83%                          | 100%              | PFS 100% (median f-up 25 months) | Rubinstein (125) |

**Table 5 continued**

| Therapy and study type | Number of patients | Stage III/IV (or risk-group) | Complete remission | Survival | Reference |
|------------------------|--------------------|------------------------------|-------------------|----------|-----------|
| ABVD (retrospective)  | 93                 | 80%                          | 74%               | 5y-EFS 59% | Montoto (119) |
| ABVD/BEACOPP (phase II) | 23              | Early favourable | 96%               | 2y-OS 96% | Hentrich (121) |
|                        | 14                 | Early unfavourable | 100%              | 2y-OS 100% |           |
|                        | 71                 | Advanced                  | 86%               | 2y-OS 87% |           |
| ABVD* (retrospective) | 68                 | 76%                          | Not reported       | 2y-PFS 89% | Besson (120) |
| ABD-BV (phase I)      | 6                  | 83%                          | 100%              | PFS 100% (median f-up 25 months) | Rubinstein (125) |

cART: combination antiretroviral therapy, ABVD: doxorubicin, bleomicine, vinblastine, and dacarbazine, Stanford V: doxorubicin, vinblastine, mecloretamine, etoposide, vincristine, bleomycin, and prednisone, BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, VEBEP: vinblastine, epirubicin, bleomycin, etoposide, and prednisone, ABD-BV: Brentuximab Vedotin, doxorubicin, vinblastine, and dacarbazine. EFS: event free survival, FFP: freedom from progression, PFS: progression free survival, OS: overall survival.

*Only 96% of patients of the series received ABVD
** Not all patients were enrolled in the cART era.
according to standard guidelines we use for HIV negative population. We perform the PET-2 evaluation and evaluate case by case if PET-2 is positive. In R/R disease we use conventional salvage CT (we prefer BeGEV) followed by ASCT in responding patients.

Prophylaxis of CNS involvement by NHL. CNS involvement by systemic NHL has been reported up to 25% in HIV positive patients, and the use of intrathecal (i.t.) prophylaxis with MTX and/or ARA-C has been long considered a mandatory part of the systemic treatment of all HIV infected patients with aggressive NHL. Even if any formal studies to evaluate the role of i.t. prophylaxis have been conducted. However, the CNS involvement has decreased since the introduction of cART and the widespread use of rituximab. A recent retrospective review of pooled data from 886 patients was recently published by Barta et al. At presentation CNS involvement was found in 13% of patients, and CNS relapses were rare, but occurred early and had poor outcomes (median OS 1.6 months). More than 90% of patients had received i.t. MTX prophylaxis. Then, the use of i.t. prophylaxis in all HIV positive patients with NHL in an era of better systemic lymphoma control remains to be defined. Most experts recommend that CNS prophylaxis, in the context of an effective cART, should be given following the same criteria as in HIV negative patients, according to different sites of involvement, stage, and histological subtype.

Autologous stem cell transplant. High dose therapy (HDT) and ASCT has been considered prohibitive in HIV positive patients for several years, at least until the introduction of cART, when groups from Europe and USA began to offer ASCT to HIV positive patients with R/R lymphoma. Then, ASCT has been demonstrated to be feasible and efficacious in several series of HIV positive patients with NHL and HL. Patients were sent to the ASCT mainly because of R/R and in few cases of high risk first CR. The results of the main series of ARL receiving ASCT are shown in Table 6. These studies showed low transplant-related mortality and durable remissions. After variable follow-up periods, DFS varied from 36-59% and OS from 36-87%, with results that mainly depended on the status of disease at the time of transplantation and an overall outcome comparable to their HIV negative counterparts. The HIV positive patients seem to experience more infectious complications in the first few months after transplant than patients without HIV that didn’t translate into a significant difference in survival, while the risk of relapse showed a trend in favor of HIV positive patients. However, these studies were mainly retrospective or recruited patients at the time of stem cell collection. In the Italian study, patients with relapsed or refractory lymphoma were recruited at the time of treatment failure, before salvage CT. 54% of the entire series of 50 patients could proceed to ASCT, with satisfactory outcome in patients who actually received transplantation (overall survival 75%) as well as good results in the entire series, with 50% of patients alive after a median follow-up of 45 months (Figure 1). A recent prospective trial from Italy analyzed the use of ASCT as upfront consolidation after CHOP, in patients with aggressive B cell lymphoma at high risk according to the IPI, and reported promising results. Of 27 enrolled patients, 15 patients received ASCT according to the protocol, and 14 are alive and relapse-free after several years from the transplant. Nowadays, HIV infection should not preclude lymphoma patients from undergoing ASCT. The same eligibility criteria as established for HIV negative lymphoma patients should be adopted for patients with HIV and the second-line therapy as induction before ASCT should consist of the same salvage regimens used for the HIV-negative population.

Allogeneic stem cell transplant. Reports of alloSCT for HIV infected patients date back to the early eighties. However, prior to effective antiretroviral therapy, alloSCT outcomes were extremely poor, with patients dying because of treatment-related toxicity or relapse. After the advent of cART, single-institution, retrospective studies with a small number of patients suggest that alloSCT may be feasible and beneficial in HIV positive patients with hematologic malignancies. A Center for International Blood & Marrow Transplant Research (CIBMTR), a registry study, reported outcomes of 23 patients receiving alloSCT (including matched related or unrelated donor transplants) for several different hematologic disorders and found that 4 of 9 patients survived in the cART era. Cumulative incidences of acute and chronic graft versus host disease (GVHD) did not appear much different than would be expected from HIV negative patients. Major causes of death were regimen-related toxicities and infections. Ten patients of this series had an NHL; however, the outcomes were not analysed separately.

The first prospective cooperative group trial of matched related or unrelated alloSCT has been recently reported. Myeloablative or nonmyeloablative regimen were used at the investigator’s discretion. Seventeen patients underwent alloSCT for treatment of acute myeloid leukemia (9), acute lymphoblastic leukemia (2), myelodysplasia (2) or lymphoma (4). There was no non-relapse mortality at 100 days. Grade II-IV GVHD developed in 41% of patients. At 24 months of median follow-up, one year OS was 57%; cause of death included disease relapse (5), acute GVHD (1), liver failure (1), and adult respiratory distress syndrome (1).

Even if data supporting the use of alloSCT are limited, most authors conclude that alloSCT should be
Table 6. Main reported series of ASCT as salvage treatment in HIV-positive patients with lymphoma.

| Reference     | n. of pts | Median age (range) | Histology (n.of pts) | Conditioning regimen (n.of pts) | PFS* | OS* | Follow-up (range) |
|---------------|-----------|--------------------|----------------------|---------------------------------|------|-----|-------------------|
| Gabarre (137) | 14        | 37 ys (27-53)      | HL (6) DLBCL (5) BL (2) PEL (1) | BEAM (5) Bu/Ara-C/Mel (1) TBI-based (8) | 4 pts alive in CR | 5 pts alive | 32 ms (14-49) |
| Krishnan (136) | 20        | 44 ys (11-68)      | HL (2) DLBCL (10) BL (6) ALCL (2) | CBV (28) TBI/Cy/Eto (4) | 85% | 85% | 32 ms (6-70) |
| Re (138)      | 27        | 39 ys (31-59)      | HL (8) DLBCL (13) BL (1) PBL (2) ALCL (2) PEL (1) | BEAM | 76% | 75% | 44 ms (4-70) |
| Serrano (141) | 33        | 42 ys (28-61)      | HL (10) DLBCL (10) BL/BLL (6) PBL (3) ALCL (3) PTCL (1) | BEAM (27) BEAC (3) TBI-based (3) | 53% at 61 ms | 61% at 61 ms | 58 ms (2-114) |
| Balsalobre (135) | 68    | 41 ys (29-62)      | HL (18) DLBCL (31) BL/BLL (8) PBL (4) ALCL (3) PTCL (3) | BEAM and variants (65) TBI-based (3) | 56% | 61% | 32 ms (2-81) |
| Spitzer (139) | 20        | 42 ys (33-60)      | HL (5) DLBCL (12) BL/BLL (3) | Dose reduced Bu/Cy | 49% | 74% | 6 ms (1-30) |
| Alvarnas (140) | 40       | 47 ys (22-62)      | HL (15) DLBCL (16) BL/BLL (7) PBL (2) | BEAM | 80% | 82% | 25 ms (3-28) |

DLBCL: diffuse large B-cell lymphoma, BL: Burkitt lymphoma, BLL: Burkitt-like lymphoma, HL: Hodgkin lymphoma, PBL: plasmablastic lymphoma, PEL: primary effusion lymphoma, ALCL: anaplastic large cell lymphoma, PTCL: peripheral T-cell lymphoma, TBI: total body irradiation, Cy: cyclophosphamide, Mel: melphalan, Bu: busulfan, Ara-C: cytarabine, Eto: etoposide, BEAM: BCNU, etoposide, cytarabine, melphalan, BEAC: BCNU, etoposide, cytarabine, cyclophosphamide, CBV: cyclophosphamide, BCNU, etoposide. TBI: total body irradiation, n.: number, pts: patients, ms: months, ys: years, PFS: progression free survival, OS: overall survival, CR: complete remission.

* PFS and OS are reported at median follow-up unless otherwise stated.

Figure 1a*. Overall survival and progression-free survival of 27 patients with HIV-related lymphoma after ASCT (Ref. 138).

Figure 1b*. Overall survival and progression-free survival of the entire series of 50 patients with HIV-related lymphoma eligible for the study (Ref. 138).

*This research was originally published in Blood. Re A, Michieli M, Casari S, et al.n High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;114:1306-13.
References:

1. AIDS: 1987 revision of CDC/WHO case definition. Bull World Health Organ. 1988; 66(2): 259-63, 269-73. PMID:2840220

2. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infectious Disease. 2010; 51: 957-962. (PubMed: 20825305) PMCID:PMC2491057

3. Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FL, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997; 73(S5):645-650. https://doi.org/10.1002/(SICI)1097-0215(19971127)73:5<645::AID-IJC637.0.CO;2-X

4. Raphael M, Said J, Borish B, Ceserman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al. (Eds): World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008.

5. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol. 2000 Aug;27(4):390-401. PMID:10950365

6. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991 Apr 1;337(8745):805-9. https://doi.org/10.1016/0140-6736(91)92513-2

7. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006, 20:1645-1654. https://doi.org/10.1097/01.aids.0000238411.75324.59

8. Dal Maso L, Polese J, Serraino D, Lise M, Piselli P, Falcini F, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer. 2009;100:840-847. https://doi.org/10.1038/sj.bjc.6604923 PMID:19223894

9. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspolti M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422. https://doi.org/10.1038/sj.bjc.6605756 PMID:20588274 PMCID:PMC2920013

10. Gibson TM, Morton LM, Shels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313-2318. https://doi.org/10.1097/QAD.0000000000000428 PMID:25111081

11. Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D’Souza G, et al. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med. 2015; 163:507-518. https://doi.org/10.7326/M14-2768 PMID:26436616

12. Shels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV Infection among U.S. Hodgkin Lymphoma cases. Cancer Epidemiol Biomarkers Prev. 2014;23:274-281. https://doi.org/10.1158/1055-9965.EPI-13-0865 PMID:24326629

13. PMCID:PMC3496161

14. Dal Maso L, Suligoi B, Franceschi S, Braga C, Buzzoni C, Polese J, et al. Survival after cancer in Italian persons with AIDS, 1980-2005: a population-based estimation. J Acquir Immune Defic Syndr. 2014;66:428-435. https://doi.org/10.1097/QAD.0000000000000184 PMID:24798769

15. Chao C, Xu L, Abrams D, et al. Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS 2010;24:1765-1770. https://doi.org/10.1097/QAD.0b013e32833a1061 PMID:20453630

16. PMCid:PMC2895006

17. Dingolangi A, Cozzi Lepri A, Teofili L, Galli L, Mazzotta V, Baldin GM, Hohaus S, Bandera A, Alba L, Galizi N, Castagna A, D’Arminio Monforte A, Antonini A; ICONA Foundation Study Group. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017 Oct 31; 12(10), 1-15. https://doi.org/10.1371/journal.pone.0186549 PMID:29088223

18. PMCid:PMC3660375

19. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100B. A Review of human carcinogenicity. IARC Monogr Eval Carcinog Risks Hum. 2012; 100Pt B1:441.

20. Kundu RK, Sangiorgi F, Wu L.Y., Pattengale PK, Hinton DR, Gill PS, Maxson R. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 1999;94:275-282. PMID:10381523

21. Dolcetti R, Giagulli C, He W, Selleri M, Cazzucchi F, Eyzaguirre LM, Mazzuca P, Corbellini S, Camplinigo F, Marsico S, Giombini E, Muraro E, Roriza G, De Paoli P, Carbone A, Capobianchi MR, Ippolito G, Fiorentini S, Blattner WA, Lu W, Gallo RC, Caruso A (2015) Role of HV-1 matrix protein p17 variants in lymphoma pathogenesis. Proc Natl Acad Sci USA 112:14331-14336. PMid:26578780

22. PMCid:PMC365530

23. Biggar RJ, Chataturvedi AK, Goedert JJ, Engels EA (2007) AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99:962-972. https://doi.org/10.1093/jnci/djm010 PMid:17565153

24. Polese J, Clifford GM, Rickenbach M, Dal Maso L, Battagay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM (2008) Non Hodgkin lymphoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. AIDS 22:301-306. https://doi.org/10.1097/QAD.0b013e32827f4d5a PMID:18097233

25. Clayton A, Meghul T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy in the post highly active antiretroviral therapy era? Hematol Oncol 2004;22:111-120. PMID:15991221

26. Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin Lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118:44-49. https://doi.org/10.1182/blood-2011-02-339275 PMID:21512334 PMCID:PMC3139385

27. Tontonzy J and Cesarman E. Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? Curr Opin Virol. 2016 October; 20:71-77. https://doi.org/10.1016/j.coviro.2016.09.001 PMID:27665065

28. PMCID:PMC5107671

29. Parka LS, Hernandez-Ramirez RU, Silverberg MJ, Broatch KA, Dubrow R (2016) Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS. AIDS 30:273-291. https://doi.org/10.1097/QAD.0000000000000922 PMID:26691548

30. PMCID:PMC4689318

31. Hunt PW (2012) HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 9:139-147. https://doi.org/10.1007/s11904-011-0118-8 PMID:22528766

32. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22-29. https://doi.org/10.1016/S1470-2045(03)00975-4

33. Gaidano G, Carbone A, Dalla-Favera R. Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. J Nat Cancer Inst Monogr. 1998;22:95-100. https://doi.org/10.1093/oxfordjournals.jncimonographs.a024181
Dehzee BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesaroni E, Chadhavkar MG, Matsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008-16. https://doi.org/10.1182/blood-2009-08-236113 PMid:20023215 PMCid:PMC2858478

55. Bartsch JA, Watson WH, Sin-Ho J, Pitcher BN, His ED, Friedberg J, Cheon B, Bartlett NL, Shih J, Pancoast J, N Fine RN, Pizzolo J, Blum K, Abramson J, Press OW, Fisher RI, Richards KL, Schoder H, Cjang JE, Zelenetz AD, Leonard JP. Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: CALGB/Alliance 50303. Blood. 2016; 130(S1): abstract n.469.

56. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Moulier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Bou F, Little RF, Dunlevy K, Wilson KH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA. Changes in the influence of lymphoma - and HIV-specific factors on outcome in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015;26:958-66. https://doi.org/10.1093/annonc/mdv036 PMid:25623071 PMCid:PMC4405278

57. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Felu E. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica. 2005:100:704-6. PMid:15921395

58. Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Abou L, Ratner L, Mitsuyasu R, Henry DM, Barr P, Noy A. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012;53:2383-89. https://doi.org/10.3109/10428194.2012.697559 PMid:22642936 PMCid:PMC3458169

59. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, Allione B, Nosari A, Scacchi E, Manni P, Puddu P, Galli G, Cattaneo C, Verga L, Ferrari S, Ferrari S, Ferrari A, Mazzuccato M, Carosi G, Tirelli U, Rossi G. High dose cytarabine and high dose chemotherapy and immunotherapy in adult Burkitt lymphoma pts: Final results of the Carmen phase II trial. Blutox. 2004;10:142(19980215)82:4<766::AID-BOX231.3.CO;2-V

60. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART era: significant differences in survival with standard chemotherapy. J Clin Oncol. 2003;21:4423-7. https://doi.org/10.1200/JCO.2003.06.039 PMid:14581441

61. Spina M, Tirelli U, Zagonel V, Gloghini A, Volpe R, Babare R, Abbrezzezz L, Talanami R, Vaccare E, Carbone A. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer Research. 1998:88:766-74. https://doi.org/10.1000/jscid.1997.0142 PMid:980215184:4<766::AID-JNCI2113.3.CO;2-V

62. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Grimwade D, Estey E, Larson R,外界 B, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernandez-Rivas JÁ, Bernal T. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study. Burkimab. Cancer. 2013;119:1660-68. https://doi.org/10.1158/0008-5472.PMda-13-2918 PMid:23361927

63. Noy A, Lee YJ, Ceseranin E, Ambrinder B, Baiocchi R, Reid E, Ratner L, Wagner-Johnston N, Kaplan L; AIDS Malignancy Consortium. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:160-66. https://doi.org/10.1182/blood-2015-01-623900 PMid:25957391 PMCid:PMC4497960

64. Dunlevy K, Pittaluga S, Shovlin M, Steinberg WM, Cole D, Grant C, Widmermann B, Staudt LM, Jaffe ES, Little RF, Wilson KH, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369:1915-25. https://doi.org/10.1056/NEJMoa130392 PMid:24224624 PMCid:PMC3901044

65. Ferreri AJM, Spina M, Cattaneo C, Verga L, Allione B, Ferrari D, Rigacci L, Fumagalli L, Donadoni G, Lleshi A, Sassone M, Rossi G, and Re A. Safety and activity of a dose-dense short-term chemotherapy in HIV-positive patients with Burkitt's lymphoma (HIV-BL pts): Final results of the Carmen phase II trial. Blutox. 2017;130(S1): abstract n.2828.

66. Delecluse HJ, Anagnostopoulos I, Dallenbach F, Himmel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhusen A, Reichart PA, Gross U, Stein H. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-20. PMid:9028965

67. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323-30. https://doi.org/10.1182/blood-2014-10-674779 PMid:2566338

68. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC,Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991-99. https://doi.org/10.1038/modpathol.2010.72 PMid:20388822

69. Castillo J, Pantanowitz L, Dezuze BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804-9. https://doi.org/10.1002/ajh.21350 PMid:18756521

70. Castillo J, Furman M, Beltran BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270-7. https://doi.org/10.1002/cncr.275511 PMid:22510767

71. Schommers P, Wyen C, Henteich M, Gillor D, Zoufaly A, Jensen B, Bogner JR, Thoden J, Wasmuth JC, Faktenheuer G, Hoffmann C. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS. 2013;27:842-5. https://doi.org/10.1097/OAD.0b013e32835e606d PMid:23574794

72. Ibrahim IF, Shapiro GA, Naima HVK. Treatment of HIV-associated plasmablastic lymphoma: a single-center experience with 25 patients. J Clin Oncol. 2014;32: abstr 8583.

73. Noy A, Lensing SY, Moore PC, Gupta N, Aboulafia D, Ambrinder B, Baiocchi R, Dezuze BJ, Henry D, Kaplan L, Levine AM, Matsuyasu R, Ratner L, Reid E, Remick S, Sparano J, Tzachanis D, Wachows M, and Chadburn A. Plasmablastic Lymphoma is Treatable in the HAART Era: A 10-year Retrospective Analysis by the AIDS Malignancy Consortium (AMC). Leuk Lymphoma. 2016; 57:1731-4. https://doi.org/10.1080/10428194.2013.1112381 PMid:26674561 PMCid:PMC4899288

74. Cattaneo C, Re A, Ungari M, Peli A, Casari S, Castelmareno F, Fisogni S, Lunardi S, Pellegrini V, Petulla M, Facchetti F, Rossi G. Plasmablastic lymphoma: a progress in human immunodeficiency virus infection in HIV-related patients: results of a single center's experience. Leuk Lymphoma. 2015;56:267-9.
A prospective study of rituximab in primary central nervous system lymphoma: natural history and response to salvage therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73:206-11. https://doi.org/10.3171/1990.73.2.0206

PMID:2366078

87. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-93. https://doi.org/10.1097/01.aids.0000083020-2003081500-00007

PMID:1276384

88. Nagai H, Odawara T, Ajsiawa A, Tanuma J, Hagiwara S, Watanabe T, Kambe T, Konishi M, Saito T, Takahama S, Tateyama M, Okada S. Whole brain radiation alone produces favourably outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol. 2010;84:499-505. https://doi.org/10.1111/j.1600-0690.2010.01424.x

PMID:20132301

89. Uldrick TS, Pippin S, Scheer S, Hessol NA: Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. AIDS. 2014;28:397-405. https://doi.org/10.1097/QAD.0000000000000300

PMID:24076659

90. Travi G, Ferreri AJ, Cinque P, Gerevini S, Ponzoni M. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol. 2012;30:119-21. https://doi.org/10.1200/JCO.2011.39.9642

PMID:22355047

91. Gupta NK, Nolan A, Omono A, Reid EG, Wang C-C, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DJ, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, and Rubenstein JL. Longer-term survival in AIDS-related primary central nervous system lymphoma. Neuro-oncology. 2017;19:99-108. https://doi.org/10.1093/neuonc/nov155

PMID:27576671

92. Moulignier A, Lamirel C, Picard H, Lebrette MG, Amiel C, Hamidi M, Polivka M, Mikol J, Cocheureau I, Piaoux G. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy. Neurology. 2017;89:1-9. https://doi.org/10.1212/WNL.0000000000004126

PMID:28747447

93. O'Neill A, Mikesch K, Fritsch K, Kasenda B, Banjerje L, Burns F, Zakout G, Johnston R, Illerhaus G, Cynkowsky K. Outcomes for HIV-positive patients with primary central nervous system lymphoma after high-dose chemotherapy and auto-SCT. Bone marrow Transplant. 2015;50:999-1000. https://doi.org/10.1038/bmt.2015.18

PMID:25867650

94. Fajgenbaum DC, Ruscalleda J, Kelleher M, Rubenstein AH. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. Lancet Haematol. 2016;3:150-2. https://doi.org/10.1016/S2352-3336(16)30007-2

PMID:27143319

95. Oksenhendler E, Bouthoul D, Fajgenbaum D, Mirouse A, Feche, M Malphettes M, Vercellino L, Meignin V, Gérard V, Gérard L, Galicier L. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol. 2018;180:206-16. https://doi.org/10.1111/bjh.15191

PMID:29143319

96. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbagila F. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:269-73. PMID:10979949

97. Hoffmann C, Schmid H, Müller M, Teutsch T, von Lanzen J, Esser S, Wolf T, Wyen S, Schabrunski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499-503. https://doi.org/10.1182/blood-2011-02-333633

PMID:21778341

98. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007;147:836-9. https://doi.org/10.7326/0003-4819-147-11-200711130-00014

PMID:17664482

99. Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, Rosenberg ML. Primary central nervous system lymphomas: natural history and response to salvage therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73:206-11. https://doi.org/10.3171/1990.73.2.0206

PMID:2366078

100. Gérard L, Béreziné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Maligne F, Boulanger E, Chretet S, Agbagila F, Oksenhendler E. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 Castlebalm Trial. J Clin Oncol. 2007;25:3350-6. https://doi.org/10.1200/JCO.2007.16.6732

PMID:18087054

101. Gérard L, Michot JM, Burcher S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbagila F, Chevet S, Oksenhendler E, Galicier L. Rituximab decreases the risk of lymphoma in patients with HIV-
associated multicentric Castleman disease. Blood. 2012;119:2228-33. https://doi.org/10.1182/blood-2012-07-290213 PMid:22688959

11. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415-21. https://doi.org/10.1182/blood-2010-07-290213 PMid:20688959

12. Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antagonist tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol. 2014;17:10. https://doi.org/10.1186/1756-7229-7-10 PMid:24438824 PMCid:PMC3896700

13. Errante D, Gabbarre J, Ridolfo AL, Rossi G, Nosari AM, Gisselbrecht C, Kernen Y, Mazzeiti F, Vacheri T, Talalamin, Carbone A, Tirelli U. Hodgkin’s disease in 35 patients with HIV infection: an experience with performic, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CEF. Ann Oncol. 1999;10:189-95. https://doi.org/10.1093/annonc/10.2.189 PMid:10039688

14. Hentrich M, Maretta L, Chow KU, Bogner JG, Schümann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin’s disease: results of a multicenter study. Ann Oncol. 2006;17:914-9. https://doi.org/10.1093/annonc/dml363 PMid:16565210

15. Castilho JB, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwinyarskii, Abramson JS, Daiia S, Biaivas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Voje MS, Xicoy B, Ribera JM. HIV-Associated Hodgkin Lymphoma in the Antiretroviral Era Study Group. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015;121:423-31. https://doi.org/10.1002/cncr.29062 PMid:25251526

16. Spina M, Antonini A, Biberia M, Manuspao S, Re A, Schiantarelli C, Talamin R, Vacher T, Tirelli U. VEBEP regimen in patients with HD and HIV infection (HD-VH): final results of a phase II study of the italian cooperative group on AIDS and Tumors (GICAT). Haematologica. 2011;96(s2):abstract n.773.

17. Spina M, Gabbarre J, Gasi F, Fasan M, Schiantarelli C, NGira E, Mena M, Antonini A, Ammassari A, Talalamin R, Vacher E, de Gennaro M, Tirelli U. Stanford five regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002; 100:984-8. https://doi.org/10.1182/blood-2002-03-0998 PMid:12200356

18. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, Valencia ME, Abella E, Lopez-Guillermo A, Sureda A, Morgades M, Navarro JT, Esteban H; GESIDA Group. GELCB Group. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica. 2007;92:191-8. https://doi.org/10.3324/haematol.10479 PMid:17296568

19. Montoto S, Shaw K, Okosun J, Gandhi S, Fiels P, Wilson A, Shanyinde M, Cwinyarskii, Marcus R, de Vos J, Young AM, Tantam-Flowers M, Oarkin C, Johnson M, Chilton D, Gribben JG, Bower M. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;34:4111-6. https://doi.org/10.1200/JCO.2011.41.4193 PMid:23045581 PMCid:PMC3520889

20. Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, Besson C, Bonnet F, Goujard C, Lambotte O, Boul F, Mouner N, Partisani M, Raffi F, Costello R, Hendel-Chavez H, Algarte-Genin M, Trabes-Pi, Marchand L, Raphael M, Taoftik Y, Costigliola D, High Risk Fibrosis. Contract With Favorable Outcomes of HIV Associated Hodgkin Lymphoma in the Modern CART Era, ANRS CO16 LYMHPHOVIR Cohort. Clin Infect Dis. 2015;61:1469-75. https://doi.org/10.1093/cid/civ627 PMid:26223997

21. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fatkenheuer G, Dietrich H, Wolf T, Rieke A, Schümann D, Schmidmaier R, Planker M, Alt J, Mostfah F, Engert A, Arasteh K, Hoffmann C. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study J Clin Oncol. 2012;30:4117-23. https://doi.org/10.1200/JCO.2012.41.1837

22. Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wohrnan A, Diehl V, BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol. 2003;14:1562-9. https://doi.org/10.1093/annonc/mdg408 PMid:14540559

23. Christova AV, Li H, Press OW, Sharabi L, Swinnen J, Martin T, Reid E, Smith SM, Friedewald JW. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma. 2017;58:461-65. https://doi.org/10.1080/10428194.2016.1201573 PMid:27386786 PMCid:PMC5130311

24. Gandhi M, Petrich A. Brentuximab vedotin in patients with relapsed HIV-related lymphoma. J Natl Compr Canc Netw. 2014;12:16-9. https://doi.org/10.6004/jncn.2014.0003 PMid:24453289

25. Rehwald U, Diehl V, Rockstroh JK, Muller M, Antinori A, Bibas M, Mancuso S, Re A, Schiantarelli C, Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Antinori A, Bibas M, Mancuso S, Re A, Schiantarelli C, Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Antinori A, Bibas M, Mancuso S, Re A, Schiantarelli C, Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, Antinori A, Bibas M, Mancuso S, Re A, Schiantarelli C.
lymphomas. Blood 2005;105:874-8. https://doi.org/10.1182/blood-2004-04-1532 PMid:15388574

137. Gabarde J, Marcelin AG, Azar N, Choquet S, Levy V, Levy Y, Tubiana R, Charlotte F, Norol F, Calvez V, Spin A, Vertan JP, Autran B, Leblond V. High dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100-8. PMid:15377471

138. Re A, Micheli M, Casari S, Allione B, Cattaneo C, Rupolo M, Spin A, Manuele R, Vaccher E, Mazzucato M, Abbruzzese L, Ferremi P, Carosi G, Tirelli U, Rossi G. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009;14:1306-13. https://doi.org/10.1182/blood-2009-02-202762 PMid:19451551

139. Spitzer TR, Ambinder RF, Lee JY, Kaplan RD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008;14:59-66. https://doi.org/10.1016/j.bbtm.2007.03.014 PMid:18158962 PMCID:PMC4524737

140. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsa J, Morris LE Jr, Thompson J, Horowitz MM, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016;128:1050-8. https://doi.org/10.1182/blood-2015-08-664706 PMid:27297790 PMCID:PMC500843

141. Serrano D, Miralles P, Carrion R, Berenguer J, Balsalobre P, Anguita J, Ribera JM, Varela R, Loscertales J, Conde E, Arranz E, Escoda L, I. Espigado I, Rodriguez G, Diez-Martin JL on behalf of cooperative groups GELTAMO/GESIDA. Long-term follow-up of autologous stem cell transplantation in AIDS-related Lymphoma patients. Results of Spanish Cooperative Registry GELTAMO/GESIDA. Bone Marrow Transplantation. 2010;45:abstract n.822.

142. Diez-Martin JL, Balsalobre P, Re A, Micheli M, Ribera JM, Canals C, Conde E, Rosselet A, Gabriel I, Varela R, Allione B, Cwynarski K, Genet P, Espigado I, Biron P, Schmitz N, Hunter AE, Ferrant A, Guillerm G, Hentrich M, Jurado M, Fernández P, Serrano D, Rossi G, Sareda A; European Group for Blood and Marrow Transplantation Lymphoma Working Party. Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009;113:6011-4. https://doi.org/10.1182/blood-2008-12-195388 PMid:19307667

143. Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16:1302-8. https://doi.org/10.1016/j.bbmt.2010.03.019 PMid:20353830 PMCID:PMC2916976

144. Re A, Gini G, Rupolo M, Levis A, Bandera A, Liberati AM, Tozzi P, Cattaneo C, Casari S, Skert C, Bocci C, Spin A, Allione B, Verga L, Michiel M, Almicci L, Leali PF, Tirelli U, Rossi G. Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk. Bone Marrow Transplant. 2018;53:229-30. https://doi.org/10.1038/bmt.2017.230 PMid:28991244

145. Bryant A, Miliken S. Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma. Biol Blood Marrow Transplant. 2008;14:601-2. https://doi.org/10.1016/j.bbmt.2008.01.010 PMid:18410904

146. Gupta V, Tamblyn M, Pedersen TL, Atkins HJ, Battwalla M, Gress RE, Pollack J, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, Horowitz MM, Keating A. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:864-71. https://doi.org/10.1016/j.bbmt.2009.03.023 PMid:19539219 PMCID:PMC2881828

147. Ambinder RF, Wu J, Logan B, et al. Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903/AIDS Malignancy Consortium (AMC-080) trial. J Clin Oncol. 2017;35:abstract n.7006